dapsa

 

 

 

DAPSA

 

The Disease Activity in Psoriatic Arthritis (DAPSA) -
Score 

 

 

 

ios dapsa

iOS version (Coming soon)
android dapsa

Android version (Coming soon)

web dapsa
Web version
pdf dapsa

Illustrative PDF (Coming soon)

pdf original dapsa

Original PDF (Coming soon)

 

What is the DAPSA score? 

 

The Disease Activity in PSoriatic Arthritis (DAPSA) is used to assess disease activity in patients with confirmed psoriatic arthritis. The score has become established, particularly in Europe, and is recommended by international experts as a measurement tool for assessing disease activity in PsA (Smolen et al. 2018). The DAPSA score includes laboratory parameters, clinical aspects, and patient self-assessments. 

How was the eDAPSA score developed? 

 

The DAPSA score was developed by Professor Dr. Smolen and colleagues at the University Hospital in Vienna with the participation of international experts and validated based on clinical data (Nell-Duxneuner et al. 2010).

 

The final score is based on four pillars: 

  1. number of joints with pressure pain (0 - 68)
  2. number of swollen joints (0 - 66)
  3. C-Reactive Protein (CRP) (mg/l)
  4. patient assessment of disease activity and pain.


In order to make the DAPSA score applicable in clinical practice, a clinical version has been developed which can be used independently of inflammatory markers. The so-called clinical DAPSA or cDAPSA score. In validation studies, a high agreement of the cDAPSA and DAPSA could be demonstrated (van Mens et al. 2018).  

How to use the eDAPSA score

 

To calculate the DAPSA or cDAPSA score, the values given above are added together in a sum score. 

dapsa screen

 

For the DAPSA:

 

 

Pressure painful joints (0 - 68) + Swollen joints (0 - 66) + C-Reactive protein (mg/l) + Disease activity + Pain.

 

To determine disease activity, the following values apply: 

  • 0 - 4 remission
  • 5 - 14 low disease activity
  • 15 - 28 medium disease activity
  • >29 high disease activity

 

 

For the cDAPSA:

 

 

Pressure painful joints (0 - 68) + Swollen joints (0 - 66) + Disease activity + Pain.

 

To determine disease activity, the following values apply: 

  • 0 - 4 remission
  • 5 - 13 low disease activity
  • 14 - 27 medium disease activity
  • >28 high disease activity


Within DermaValue, the DAPSA score and cDAPSA score are calculated automatically and the possibility is given to save the completed score as a PDF.
 

 

Following you can find the versions of the DAPSA

ios dapsa

iOS version (Coming soon)

android dapsa

Android version (Coming soon)

web dapsa
Web version
pdf dapsa

Illustrative PDF (Coming soon)

pdf original dapsa

Original PDF (Coming soon)

 

Features

 

use icon psa

EASY TO USE
 

The joint status sheet can now be filled out quickly and easily online. 

nature icon psa

SAVE PAPER
 

Take care of the environment! The simple DAPSA form can be filled out online and easily saved to your records, eliminating un-necessary printouts. 

patient icon psa

DOCUMENTATION
 

Simply save your results as a PDF file! For your documentation and for forwarding to your patient.

calculate icon psa

VALIDATED
 

The joint status sheet is based on the worldwide-recognized DAPSA-SCORE and has already been used in many international studies. 

Our Further Tools

 

epbi
epasi
edlqi
eeasi
ewound qool
epain
enappa
eflqa
eitch

 

References

Augustin, Matthias; Spehr, Christina; Radtke, Marc A.; Boehncke, Wolf-Henning; Luger, Thomas; Mrowietz, Ulrich et al. (2014): German psoriasis registry PsoBest: objectives, methodology and baseline data. In: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 12 (1), S. 48–57. DOI: 10.1111/ddg.12233.


Nell-Duxneuner, Valerie P.; Stamm, Tanja A.; Machold, Klaus P.; Pflugbeil, Stephan; Aletaha, Daniel; Smolen, Josef S. (2010): Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. In: Annals of the rheumatic diseases 69 (3), S. 546–549. DOI: 10.1136/ard.2009.117945.


Smolen, Josef S.; Schöls, Monika; Braun, Jürgen; Dougados, Maxime; FitzGerald, Oliver; Gladman, Dafna D. et al. (2018): Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. In: Annals of the rheumatic diseases 77 (1), S. 3–17. DOI: 10.1136/annrheumdis-2017-211734.


van Mens, Leonieke J. J.; van de Sande, Marleen G. H.; van Kuijk, Arno W. R.; Baeten, Dominique; Coates, Laura C. (2018): Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. In: Annals of the rheumatic diseases 77 (2), S. 251–257. DOI: 10.1136/annrheumdis-2017-211998

Our Partners

 

uke
psonet
cvderm
ddg
bvdd
hautnetz